EPISODE · Dec 2, 2022 · 11 MIN
MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy
from MPR Weekly Dose
FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review.
Embed this episode
Ready to play
MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy
0:00
11:36
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 11 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on December 2, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!